These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31330099)

  • 1. Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression.
    Moreno-Yruela C; Fass DM; Cheng C; Herz J; Olsen CA; Haggarty SJ
    ACS Chem Neurosci; 2019 Aug; 10(8):3769-3777. PubMed ID: 31330099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia.
    She A; Kurtser I; Reis SA; Hennig K; Lai J; Lang A; Zhao WN; Mazitschek R; Dickerson BC; Herz J; Haggarty SJ
    Cell Chem Biol; 2017 Jul; 24(7):892-906.e5. PubMed ID: 28712747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia.
    Holler CJ; Taylor G; McEachin ZT; Deng Q; Watkins WJ; Hudson K; Easley CA; Hu WT; Hales CM; Rossoll W; Bassell GJ; Kukar T
    Mol Neurodegener; 2016 Jun; 11(1):46. PubMed ID: 27341800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients.
    Almeida S; Gao F; Coppola G; Gao FB
    Neurobiol Aging; 2016 Jun; 42():35-40. PubMed ID: 27143419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
    Koppel I; Timmusk T
    Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
    Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
    Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing progranulin levels and blockade of the ERK1/2 pathway: upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia.
    Alquezar C; Esteras N; de la Encarnación A; Moreno F; López de Munain A; Martín-Requero Á
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):386-403. PubMed ID: 25624003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects.
    Almeida S; Zhang Z; Coppola G; Mao W; Futai K; Karydas A; Geschwind MD; Tartaglia MC; Gao F; Gianni D; Sena-Esteves M; Geschwind DH; Miller BL; Farese RV; Gao FB
    Cell Rep; 2012 Oct; 2(4):789-98. PubMed ID: 23063362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients.
    Valdez C; Wong YC; Schwake M; Bu G; Wszolek ZK; Krainc D
    Hum Mol Genet; 2017 Dec; 26(24):4861-4872. PubMed ID: 29036611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase as a new target for cancer chemotherapy.
    Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.
    Chou CJ; Herman D; Gottesfeld JM
    J Biol Chem; 2008 Dec; 283(51):35402-9. PubMed ID: 18953021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
    Yue K; Qin M; Huang C; James Chou C; Jiang Y; Li X
    Bioorg Med Chem Lett; 2022 Aug; 70():128797. PubMed ID: 35580726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial.
    Ljubenkov PA; Edwards L; Iaccarino L; La Joie R; Rojas JC; Koestler M; Harris B; Boeve BF; Borroni B; van Swieten JC; Grossman M; Pasquier F; Frisoni GB; Mummery CJ; Vandenberghe R; Le Ber I; Hannequin D; McGinnis SM; Auriacombe S; Onofrj M; Goodman IJ; Riordan HJ; Wisniewski G; Hesterman J; Marek K; Haynes BA; Patzke H; Koenig G; Hilt D; Moebius H; Boxer AL
    JAMA Netw Open; 2021 Sep; 4(9):e2125584. PubMed ID: 34559230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia.
    Rosenthal ZC; Fass DM; Payne NC; She A; Patnaik D; Hennig KM; Tesla R; Werthmann GC; Guhl C; Reis SA; Wang X; Chen Y; Placzek M; Williams NS; Hooker J; Herz J; Mazitschek R; Haggarty SJ
    Sci Rep; 2024 Apr; 14(1):9064. PubMed ID: 38643236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
    Furumai R; Komatsu Y; Nishino N; Khochbin S; Yoshida M; Horinouchi S
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):87-92. PubMed ID: 11134513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progranulin deficiency induces overactivation of WNT5A expression via TNF-α/NF-κB pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers.
    Alquézar C; de la Encarnación A; Moreno F; López de Munain A; Martín-Requero Á
    J Psychiatry Neurosci; 2016 Jun; 41(4):225-39. PubMed ID: 26624524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia.
    Cenik B; Sephton CF; Dewey CM; Xian X; Wei S; Yu K; Niu W; Coppola G; Coughlin SE; Lee SE; Dries DR; Almeida S; Geschwind DH; Gao FB; Miller BL; Farese RV; Posner BA; Yu G; Herz J
    J Biol Chem; 2011 May; 286(18):16101-8. PubMed ID: 21454553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases.
    Cleophas MC; Crişan TO; Lemmers H; Toenhake-Dijkstra H; Fossati G; Jansen TL; Dinarello CA; Netea MG; Joosten LA
    Ann Rheum Dis; 2016 Mar; 75(3):593-600. PubMed ID: 25589513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.
    Srinivas NR
    Xenobiotica; 2017 Apr; 47(4):354-368. PubMed ID: 27226420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.